Why Choose Private Prescription Over NHS Waiting Lists?
Private Prescription Wegovy Vs Mounjaro: Bypassing NHS Delays
The NHS route for accessing Wegovy vs Mounjaro typically requires GP referral to specialist weight management services, with current waiting times averaging 6-8 months across most UK regions. Private prescription eliminates this bottleneck entirely, allowing direct access to both treatments through qualified prescriber assessment. EverydayMeds provides identical Novo Nordisk Wegovy and Eli Lilly Mounjaro to NHS services, but without the restrictive criteria and lengthy delays that characterise public healthcare provision.
When comparing Wegovy vs Mounjaro through private prescription, patients gain control over timing and treatment selection. Our clinical team can assess suitability for either medication based on individual medical history, lifestyle factors, and treatment preferences. This personalised approach ensures the most appropriate choice between semaglutide's established GLP-1 pathway and tirzepatide's innovative dual-hormone mechanism, both delivered through the same streamlined private prescription process.
Wegovy Vs Mounjaro Pricing: Transparent Private Prescription Costs
Understanding the financial commitment when choosing between Wegovy vs Mounjaro helps inform treatment decisions. Wegovy pricing starts at £79.99 for 0.25mg starter dose (with FIRST40 discount for new customers), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for maintenance 2.4mg dose. Our Getting Started bundles provide convenient dose progression options, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, supporting the mandatory dose escalation protocol.
Mounjaro pricing follows a different structure reflecting its dual-agonist formulation, with transparent costs provided during prescriber consultation. Both treatments qualify for our discount codes — FIRST40 for new patients and DOSE25 for returning customers — applied automatically at checkout. When weighing Wegovy vs Mounjaro costs, consider the complete treatment journey including dose escalation phases, with our bundled options designed to provide multi-month supply security without repeated ordering.
Clinical Evidence: Wegovy Vs Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different populations, with STEP 2 showing 9.6% weight reduction in patients with type 2 diabetes and STEP 3 achieving 16% loss with intensive behavioural therapy. The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, expanding Wegovy's clinical utility beyond weight management.
Mounjaro's SURMOUNT trials demonstrated the potential of dual GIP/GLP-1 receptor agonism, though direct comparison with Wegovy vs Mounjaro efficacy requires careful consideration of different trial designs and patient populations. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity to achieve optimal outcomes. Individual response varies considerably, making prescriber guidance essential when selecting between these evidence-based therapies.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone glucagon-like peptide-1 produced in the intestines after eating. This mechanism reduces appetite by acting on brain centres that control food intake, specifically the hypothalamus where appetite regulation occurs. Patients typically experience enhanced satiety after smaller meals, reduced food cravings between meals, and slower gastric emptying that prolongs feelings of fullness. The once-weekly injection provides sustained hormone activity, maintaining appetite suppression throughout the dosing interval. Clinical studies suggest this mechanism may also influence reward pathways associated with food-seeking behaviour, though individual responses to GLP-1 receptor activation vary significantly between patients.
Streamlined Ordering Process: 3-Minute Assessment to Delivery
Our private prescription service transforms the typically complex Wegovy vs Mounjaro selection process into a straightforward 3-minute online clinical assessment covering medical history, current medications, weight management goals, and lifestyle factors. Following submission, qualified prescribers review applications within 3 working days (or 24 hours with express service), evaluating suitability for either treatment based on MHRA-approved criteria and individual patient factors. Once approved, your chosen prescription-only medicine ships via next-day delivery using temperature-controlled cold-chain logistics, ensuring medication integrity throughout transit. Our GPhC-registered pharmacy (#9012878) maintains pharmaceutical-grade storage and handling protocols, delivering genuine manufacturer products directly to your address. This efficient pathway eliminates traditional healthcare bottlenecks whilst maintaining clinical safety standards throughout the prescribing and dispensing process.
Storage Advantages: Wegovy Vs Mounjaro Practical Considerations
When comparing Wegovy vs Mounjaro for practical daily use, storage requirements present a notable difference favouring Wegovy's flexibility. Both medications require refrigeration at 2-8°C before first use, but Wegovy tolerates up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage proves particularly valuable for business travellers, holiday periods, or situations where refrigeration access becomes limited, making Wegovy more accommodating for active lifestyles. The FlexTouch pen delivery system used for Wegovy provides intuitive dose administration with clear dosing windows and reliable injection mechanisms. Both treatments follow mandatory dose escalation schedules to minimise gastrointestinal side effects, but Wegovy's established 5-dose progression (0.25mg to 2.4mg over 16 weeks) offers well-documented tolerability profiles developed through extensive clinical experience.
Choosing Between Wegovy Vs Mounjaro: Private Prescription Flexibility
The decision between Wegovy vs Mounjaro through private prescription allows personalised treatment selection based on individual medical profiles rather than restrictive NHS protocols. Patients with previous GLP-1 experience might benefit from Mounjaro's dual-agonist approach, whilst those seeking established long-term data may prefer Wegovy's extensive STEP trial programme and cardiovascular outcome evidence. Private prescription enables switching between treatments if initial response proves suboptimal, providing therapeutic flexibility unavailable through rigid NHS pathways.
Our prescriber team evaluates factors including existing medical conditions, concurrent medications, lifestyle demands, and patient preferences when recommending between Wegovy vs Mounjaro options. This individualised approach recognises that weight management requires tailored solutions rather than one-size-fits-all protocols, ensuring the selected prescription-only medicine aligns with personal circumstances and treatment objectives for optimal long-term success.
Complete Your Order: Discount Codes and Expert Support
Both Wegovy and Mounjaro are available through EverydayMeds' private prescription service, with your prescriber helping determine which treatment best suits your individual needs and medical profile. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for continued savings on their chosen therapy. Our clinical assessment takes just 3 minutes to complete, connecting you with qualified prescribers who understand the nuances of choosing between Wegovy vs Mounjaro for sustainable weight management. Visit https://everydaymeds.co.uk/collections/wegovy to begin your private prescription journey today. Remember that both treatments are prescription-only medicines requiring professional oversight and must be used alongside a reduced-calorie diet and increased physical activity for optimal results, with ongoing support available from our GPhC-registered pharmacy team (#9012878).
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
